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The potencies and etticacies ofseven agonists at chick c f nicotinic receptors expressed in donut oacytes were detrains by whole cell rmrding. 
(+f-Anatoxin-a was the most potent agonist (EC, = 0.58 @vi) and a~tylcholine was the least potent (EC,, = 320 PM). The rank order of agonist 
potencies was: (+)-anatoxin-a >:, cytisine > (-)-nicotine > (+)-nicotine t DMPP Z 1-acetyl-4-methylpiperazine methiodide > acetylcholine. DMPP 
evoked only very small currents: comparison of maximally effective agonist concentrations howed that DMPP was only one-fifth as efficacious 
as other agonists. Previously published IC,, values for rat brain [‘251]a-bungarotoxin sites show a similar agonist profile, and the identity of 
bomo-oligome~c a7 receptors with native ~-bungarotoxin-sensitive n uronal nicotinic receptors is discussed. 
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The a7 nicotinic acetyl~holine r ceptor (nAChR) sub- 
unit is unique among vertebrate nAChR subunits char- 
acterised so far in its ability to form robust homo-oli- 
gomeric channels when expressed in Xenopus oocytes 
[1,2]. The expressed a7 channels respond to ace- 
tylGholine (ACh) and nicotine, desensitise very rapidly 
and are sensitive to ~“bungarotoxin (aBgt), curare and 
dihydro-~-erythroi~~e [ 1,3]. Antibodies raised against 
bacterially-expressed a7 gene product indicate that at 
least 90% of ~Bgt-bin~ng proteins in the chick brain 
contain this subunit [4,5]. Until the cloning and char- 
acterisation of the ~27 cDNA, the rela~onship between 
brain olBgt binding sites and nAChR was ambiguous 
[6]: although olBgt binding sites have a clear nicotinic 
profile in binding assays [7], the failure of clBgt to antag- 
onise the majority of centrally-mediated nicotinic re- 
sponses raised questions about the function of these 
proteins. More recent studies on autonomic neurons 
[8,9] have revealed that aBgt-sensitive nAChR are func- 
tional but their activity is eclipsed by the dominant 
nAChR subtype mediating conventional synaptic trans- 
mission. In the CNS, it is not known if aBgt-sensitive 
nAChR perform the same fictions as in autonomic 
neurons. However, IBM-sensitive channds have been 
demonstrated by ~t~h~larnp analysis of cultured hip- 
pocampal neurons [l&l 1,121. These channels show the 
rapid desensitisation characteristic of a7 nAChR. 
Thus there is good evidence that a7 subunits cantrib- 
ute to neuronal clBgt-sensitive nAChR. What is not 
known is whether other subunits are present in the na- 
tive protein. Protein chemistry has suggested between 1 
and 4 subunits in the ~Bgt-binding protein [I 3,141 and 
antibody studies have indicated that some 20% of a7- 
containing nAChR in chick brain also contain the re- 
lated a8 subunit [5]. One approach to the comparison 
of a7 and native aBgt binding sites is to compare their 
pha~a~ological specificities and sensitivies. bed-rigid 
agonists, stereoisomers and structural analogues can be 
particularly discriminating. Here we have examined the 
effects of seven agonists on a7 nAChR expressed in 
Xe~~opus oocytes, for comparison with published bind- 
ing data for brain membranes. 
2. E~ERIMENTAL 
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~bbrev~~i#~s: nAChR, nicotinic acetylcholine receptor; aBgt, d-bun- 
garotoxin; DMPP, 1, I-dimethyl-4.phenyipi~~nium iodide; AMP 
MeI, I-a~tyl-4.methylpiper~ine methiodide. 
Xetwpus oocytes were injected with 2 ng of a7 cDNA [l]” Electro- 
physiological recording was performed 2-5 days later using a conven- 
tional dual electrode voltage clamp. Cells were clamped at -70 mV 
and perfused (IO mllmin) with modified Barth’s solution (NBS: NaCl 
88 mM, KC1 1 mM, HEPEiS 10 mM, MgSC& 0.82 mM C&NO& 0.33 
mM, CaCl, 0.91 mM, NaHCO, 2.4 mM, pH 7.5) containing 0.5 PM 
atropine. Agonists were applied in perfusion as 3 s pulses. Data were 
stored on a digital-to-analogue DAT converter and processed using 
the acquisition and analysis programs AQ and PAT2L flS] and Sigma- 
plot version 4.1. Dose-response curves were fitted to the non-linear 
Hill equation: y = l/ ( ~~~~C~X~~)~ where x = agonist concentration 
and nH = Hill number. 
Materiak (-)-Nicotine base, ACh-HCl and cytisine were from Sigma 
Chemical Co., Poole Dorset, UK, DMPP I was from Aldrich, Gilling- 
ham, Dorset, and (+)-nicotine hydrogen tartrate was from BDH, 
Volume 327, number 3 FEBSLE~ER~ August 1993 
Poole, Dorset. (+)-Anatoxin-a was provided by Dr. E.X. Albuquerque 
and AMP MeI was provided by Dr. I. Stolerman. Stock solutions (10 
mM) of agonists, except AMP MeI, were made up in MBS and ad- 
justed to pH 7.5 if necessary. Because of the low solubility of AMP 
MeI, a stock solution (50 mM) was prepared in DMSO. Aliquots were 
stored at -20°C thawed on the day of use and diluted in MBS 
containing 0.5 PM atropine. Control samples of diluted DMSO (no 
agonist present) were used to confirm that DMSO itself had no effect 
on oocytes expressing ~7. 
3. RESULTS 
Nuclear injection of d7 cDNA into Xenopus oocytes 
resulted in responses to nicotinic agonists when tested 
2-5 days later. Large currents, typically 0.2-2 ,uA, were 
recorded (Fig. l), and these displayed characteristic fast 
onset and rapid desensitisation at higher agonist con- 
centrations [l]. Currents evoked by (-)-nicotine were 
completely blocked by 10 nM a-cobratoxin with no 
recovery following 30 min of washing, whereas 10 nM 
methyllycaco~tine produced a complete blockade that 
was slowly reversible. Several agonists were investigated 
for their abilities to activate nicotinic currents (Fig. 1): 
a range of agonist concentrations was tested on a single 
oocyte and dose-response curves of the peak currents 
averaged from several such experiments. (+)-Anatoxin- 
a was clearly the most potent agonist, with an ECso 
value of 0.58 PM, whereas ACh (EC,, = 320 PM) was 
the least potent (Table I). Intermediate potencies were 
observed for cytisine (5.6 PM), (-)-nicotine (24 PM), 
(+)-nicotine (45 PM), and DMPP (64 PM). Hill slopes 
were greater than one (Table I), consistent with the 
binding of more than one agonist molecule for activa- 
tion; (~)-anatoxin-a and (+)-~cotine produced steeper 
curves than the other agonists. 
When agonist dose-response data were normalised 
with respect to (-)-nicotine (Fig. I), it was clear that 
DMPP elicited much smaller responses than (-)-nico- 
tine despite having comparable potency. A similar effect 
on a7 nAChR was noted by Bertrand et al. [3]. To 
explore this further, we examined the structurally re- 
lated compound 1-acetyl-4-methylpiperazine methio- 
dide (AMP MeI) [16]. The dose-response curve for 
AMP Me1 (Fig. 1) gave an EC, of 170 PM (Table I) 
and the rnax~~ response was 70% of the maxims 
Fig. 1. Dose-response data for agonists activating a7 nAChR. (A) 
Superimposed inward currents recorded from two oocytes, each ex- 
posed to 3 set pulses of increasing concentrations of agonist. Ten 
minute intervals were given between each agonist pulse to allow full 
recovery from desensitisation, Vn = -70 mV. Left: (-)-nicotine 
5 x 10m6, 5 x 10m5, 2 x 10m4 M; Right: DMPP 1 x 10e6, 3 x 10d5, 
1 x IO-‘M. (B,C,D) Dose-response curves compiled from data from 
several oocytes, and normal&d against (-)-nicotine (2.5 x 10e4 M) 
applied to the same oocyte. Symbols represent he mean data points 
with S.E.M. indicated by the vertical bars. Lines represent the theoret- 
ical dose-response curve fitted to the data points using the non-linear 
Hill equation (see section 2). (B) l -O, (-)-nicotine; V-V, (+)-nicotine; 
(C) R-m, (+)-anatoxin-a; o-o, ACh; (D) +-t, AMP Mel; n-n, DMPP. 
B 
(-)nic 
a 
~ 
SOOnA L 
1B 
120 
100 
80 
60 
40 
20 
120 
100 
80 
60 
40 
20 
0 
DMPP 
- 
=TT== 
IIf- 5OnA 
L 
ir 
-8 -7 -6 -5 -4 -3 -2 
-8 -7 -6 -5 -4 -3 -2 
100 
D 80 
60 
40 
20 
0 
-8 -7 -6 -5 -4 -3 -2 
log [agonist] (M) 
285 
Volume 327, number 3 FEBSLETTERS August 1993 
Table I 
Potencies of nicotinic agonists at reconstituted chick a7 nAChR; comparison with ligand binding data for rat brain 
Agonist EC,, (M) nii Rel. potency K (W Rel. potency EGdK 
a7 W,,) aBgt binding to rat brain (K,) 
(+)-Anatoxin-a 5.8 + 0.9 x 10-7 (5) 2.6 It 0.3 41 9.1 x lo+= 97 6.4 
Cytisine 5.6 + 1.3 x lo-+ (7) 1.9 + 0.2 23 1.1 x 10-6b 8 5.1 
(-)-Nicotine 2.4 + 0.7 x 1O-5 (44) 1.4ro.1 1 8.9 x lo+’ 1 2.7 
(+)-Nicotine 4.5 k 1.0 x lo-5 (3) 2.5 + 0.7 0.53 5.2 x lo-5c 0.17 0.8 
DMPP 6.4 f 2.7 x 1O-5 (7) 2.0 r 0.2 0.37 7.6 x lo-6d 1.2 8.4 
AMP Mel 1.7 r 0.3 x lo+ (5) 1.3 rt: 0.1 0.14 3.7 x lo+ d 0.24 4.6 
ACh 3.2 2 1.5 x lo+ (5) 1.8 zk 0.3 0.07 1.1 x Io-sc 0.8 29.1 
Data from: “ref. [7]; ‘ref. [21]; ‘ref. [18]; %ef. [16]; ‘unpublished. 
response to (-)-nicotine. The efficacies of agonists were points for higher concentrations of the drug. Such val- 
compared by applying maximally effective concentra- ues could not be obtained due to the limited availability 
tions of each one to the same oocyte in succession (Fig. and low solubility of AMP MeI. Efficacy comparisons 
2). This confirmed the relative efficacies indicated by the were also carried out with E&, concentrations of the 
normalised dose-response curves. In particular, DMPP agonists. These experiments confirmed that AMP MeI 
responses were 20% of those of (-)-nicotine whereas is at least three times more efficacious than DMPP. 
AMP Me1 gave 46% of the (-)-nicotine response. The Cu~ent-voltage relationships were determined for 
plateau level of the AMP Me1 dose-response curve (and each agonist and the results are depicted in Fig. 3. The 
hence the concentration used in Fig. 2) may be underes- seven agonists behave similarly, responses decreasing as 
timated by the curve fit (Fig. 1) in the absence of data the membrane potential is stepped from -100 to -40 
Fig. 2. Efficacy of agonists compared at maximally effective concentrations. Six agonists were tested sequentially on the same oocyte at maximally 
effective agonist concentrations: (+)-anatoxin-a (4,oM); (-)-nicotine (250&M); (+)-nicotine (3OOpM); DMPP (1 mM); AMP Me1 (I mM) and ACh 
(4 mM). Current responses were normalised with respect o currents evoked by 250 PM (-)-nicotine. Oocytes were clamped at -70 my 12 min 
intervals were allowed between agonist applications. Values are the mean It S.E.M. from 5 individual oocytes. Insert: representative current traces. 
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Fig. 3. Current-voltage relationships for six agonists. Applications (3 
s) of an agonist were given at 12 min intervals while stepping the 
holding potential from -100 mV to +20 mV. Current responses were 
normalised with respect o the response observed at -100 mV Agonist 
concentrations approximated to their EC,,, concentrations: M-I, (+)- 
anatoxin-a 5 x lo-’ M; r-7, cytisine 5 x 10v6 M; O-O, (-)-nicotine 
2.5 x lo-’ M; A-A, (+)-nicotine 4 x IO-’ M; A-A, DMPP 6 x lo-’ M; 
a-+, AMP Mei 1 x IO-“ M; o-o, ACh 2 x 10e4 M. 
mV, followed by marked inward ratification at more 
positive potentials. 
4. DISCUSSION 
These results extend the quantitative agonist profile 
of the a7 nAChR. ECso values for (-)-nicotine and ACh 
are in good agreement with those previously described 
[3] but cytisine was more potent in the present study. In 
addition, (+)-anatoxin-a is shown to be the most potent 
agonist, as it is at other nAChR [17], while (+)-nicotine 
is two-fold weaker than the naturally occurring enanti- 
omer. Such slight stereo~l~tivity in favour of (-)-nico- 
tine is a property of aBgt-sensitive sites in Torpedo and 
brain [18], and is in marked contrast to aBgt-insensitive 
nAChR which show a loo-fold preference for (-)-nico- 
tine [19]. Interestingly, DMPP was a relatively potent 
agonist at a7 nAChR but displayed only 20% of the 
efficacy of (-)-nicotine. Bertrand et al. [3] reported that 
DMPP elicited no significant currents in oocytes ex- 
pressing a7. Current responses were somewhat larger in 
the present study and this may have enabled the detec- 
tion of DMPP-evoked responses. An a7 subunit re- 
cently cloned from rat brain [2] also showed anomalous 
dose-de~ndency for DMPP, and raised the suggestion 
that it might have channel blocking activity. Visual in- 
spection of (-)-nicotine and DMPP-evoked current 
traces (Fig. 1) shows no obvious differences between 
these two agonists in the rates of activation or desensiti- 
sation, but the fast desensitisation shown by a7 nAChR 
and the limits of resolution imposed by the whole cell 
recording technique make it difficult to discern the 
mode of action of DMPP. Analysis is further compli- 
cated by the contribution to the a7 responses of a sec- 
ondary Ca”-activated chloride current [2], Single chan- 
nel analysis will be necessary to determine the precise 
mechanism that accounts for the small responses ob- 
served with DMPF? The structurally related compound 
AMP Me1 was at least 3 times more efficacious than 
DMPP and may be a fully effective agonist. Thus the 
common piperazine group is insufficient to explain the 
results observed with DMPI? 
In Table I, the EC& values for agonists are compared 
with their K, values for binding to [iz51]aBgt sites in rat 
brain membranes, previously determined in this labora- 
tory. A similar rank order is observed in the two series, 
but $ values are approximately five-fold lower than 
EC,, values. However, concordance is not expected as 
equilibrium binding assays are likely to reflect binding 
to the desensitised state of the nAChR, and this is asso- 
ciated with higher affinity [20]. The agonists showing 
greatest deviation from the general relationship between 
EC, and K, are (+)-nicotine, which is rather more po- 
tent than predicted by the binding data, and ACh, 
which is less potent than expected. These discrepancies 
might arise from species differences between chick and 
rat, or may reflect the absence of additional subunits in 
the reconstituted nAChR compared to the native recep- 
tor. However, aBgt-sensitive nAChR character&d in 
rat hippocampal neurons (Type IA) [ 1 l] have a sensitiv- 
ity to ACh comparable to that of a7, and the rank order 
of agonist potencies is similar. Nevertheless an impor- 
tant difference between the native and reconstituted 
nAChR is that DMPP is as efficacious as ACh at 
nAChR in hippocampal cells [l I]. Secondly, current- 
voltage relationships for agonists in these neurons may 
differ from those of a7 nAChR: rectification of a7 cur- 
rents at about -30 mV (Fig. 3) agrees well with the data 
of Couturier et al. [I], whereas aBgt-sensitive nAChR 
in hipp~ampal neurons have a slightly positive reversal 
potential and may [ 10,121 or may not [ 1 l] show rectifica- 
tion. Additional subunits in the native protein could 
account for these differences. Co-expression studies are 
now required to examine these more complex properties 
of nicotinic currents, to determine if they are influenced 
by structural subunits. 
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